Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant capsules
- Development stage
- Phase 2
- Lead developer
- Amsterdam UMC
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplant (FMT) capsules, specifically the lyophilised fecal microbiota capsules (LFMCs) developed by Amsterdam UMC, are an investigational microbiome-based therapeutic. These oral capsules contain freeze-dried fecal microbiota obtained from healthy vegan donors. The therapy is designed to modulate the gut microbiome to address the gut-liver axis, aiming to reduce hepatic necroinflammation and steatohepatitis. In clinical studies (notably NCT05821010), they are being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), typically administered in conjunction with a synbiotic cocktail consisting of *Anaerobutyricum soehngenii*, pasteurized *Akkermansia muciniphila*, *Bifidobacterium animalis* subsp. *lactis*, and fructo-oligosaccharides.
- Other names
- lyophilised fecal microbiota capsulesconditioned fecal microbiota transplantation capsules
Beyond the preview
Go deeper on fecal microbiota transplant capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant capsules.